About: http://data.cimple.eu/news-article/4722dce19e94b6f75865d61a5aa1db9b01b23e395e3d5aaa43001f27     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • US biotech firm Novavax said its Covid-19 vaccine candidate showed 89.3 efficacy in a major phase 3 clinical trial involving more than 15,000 people. "NVX-CoV2373 has the potential to play an important role in solving this global public health crisis," said the company's president and CEO Stanley Erck. But the positive news was offset by results that showed it was much less effective against a highly transmissible variant of the coronavirus first identified in South Africa that is spreading quickly around the world. ia/ft
schema:headline
  • Novavax says Covid-19 vaccine has 89% efficacy in major trial
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software